Objective The aim of this study was to elucidate the efficacy of short-term interferon (IFN) 
Introduction

Current interferon (IFN) therapy for patients with chronic hepatitis C viral infection has been directed at viral clearance. Recent studies reported improvement of therapeutic efficacy when IFN is combined with ribavirin (1-5). Moreover, novel long-acting formulations of IFN known as pegylated IFN induced higher eradication rate of hepatitis C virus (HCV)
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On the other hand, serum HCV-RNA at 6 months after the termination of IFN therapy was analyzed by the qualitative PCR assay or RT-nested PCR. The lower detection limit of the qualitative assay is 100 copies/ ml. HCV genotype was examined by the PCR assay, using a mixture of primers for the six subtypes known to exist in Japan, as reported previously (19) .
Liver histology
Liver biopsy specimens were obtained percutaneously or by peritoneoscopy using a modified Vim Silverman needle (20) . T a b l e 3 . P r e d i c t i v e F a c t o r s f o 
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T a b l e 4 . S VR B a s e d o n HCV Ge n o t y p e a n d Ad mi n i s t r a t i o n P e r i o d o f I n t e r f e r o n the 8-week regimen was similar statistically to that in patients treated with the 4-or 6-week regimen.
Conclusion
We think that the 6 or 8-week regimen of IFN-beta therapy is one therapy selection for chronic hepatitis C patients who tend to have a SVR and have IFN-induced adverse events.
